The remaining patients were patients with right or left colon tumors and we compared the overall survival (OS), molecular mutations (KRAS, NRAS, BRAF, MSI status), and clinicopathological features of our patients with transverse colon tumors with these patients. This evidence concerns the gene NRAS and colonic neoplasm.